The FDA granted RMAT designation to DiscGenics’ Injectable Disc Cell Therapy for degenerative disc disease.
MMI co-founder, Dr. John Hipp, was recognized for his outstanding contributions to spine basic research.
In the face of an aging population and the demand for cost-effective solutions, spine surgeons hold the targeted insight necessary to determine which devices will find a warm welcome in the market.
A recent study took advantage of Medical Metrics state-of-the-art Quantitative Motion Analysis, or QMA®, software to track the motion of cervical disk replacements with extreme precision.
